3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Polycystic Ovary Syndrome
91
Breast Neoplasms
21
Insulin Resistance
18
Obesity
14
Prostatic Neoplasms
10
Pancreatic Neoplasms
8
Endometrial Neoplasms
7
Neoplasms
6
Infertility
6
Anovulation
6
Neoplasm Metastasis
5
Colorectal Neoplasms
5
Rectal Neoplasms
4
Hyperandrogenism
4
Weight Loss
3
Squamous Cell Carcinoma of Head and Neck
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lung Neoplasms
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hyperinsulinism
3
Head and Neck Neoplasms
3
Diabetes Mellitus, Type 2
3
Diabetes Mellitus
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Recurrence
2
Rare Diseases
2
Premature Birth
2
Overweight
2
Ovarian Neoplasms
2
Interventions
Insulin Glargine
2
Insulin
2
Alpelisib
2
ziprasidone
1
relacorilant
1
pembrolizumab
1
exemestane
1
Vildagliptin
1
Tamoxifen
1
Olanzapine
1
Metformin
1
Letrozole
1
Insulin Lispro
1
Injections
1
Fulvestrant
1
DNA, Ribosomal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hyperglycemia
×
Metformin
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled